Effect of a Combination Oral Formulation of Hyaluronic Acid, Chondroitin Sulphate and Magnesium Trisilicate in Patients With Gastro-Esophageal Reflux Disease Not Fully Satisfied With Their Treatment

Gastro Esophageal Reflux Clinical Trial

Official title:

Evaluation of the Performance and Safety of an Oral Formulation of Hyaluronic Acid With Chondroitin Sulphate and Magnesium Trisilicate (GERDOff® Plus) in Patients With Gastro-Esophageal Reflux Disease: A Double-blind, Placebo-controlled, Randomized, Cross-over Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04202692
• Other study ID #: PSC-DS MATRIX 19
• Status: Completed
• Phase: N/A
• Start date: November 5, 2019
• Est. completion date: November 23, 2022

Study information

• Verified date: April 2023
• Source: SOFAR S.p.A.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a post-market, multi-center, double-blind, placebo-controlled, randomized, cross-over study with GERDOff Plus added on top of the current PPI treatment in patients with GERD. The aim of the study is to evaluate the performance of GERDOff Plus, a class III medical device, consisting in a hyaluronic acid, chondroitin sulphate and magnesium trisilicate, in addition to the PPIs, in patients with GERD not fully satisfied with their current treatment with PPIs.

Patients will receive either GERDOff Plus or placebo q.i.d. for 21 days followed by a wash-out period of 3 weeks. After the wash-out period, the patients will receive either placebo or GERDOff Plus respectively

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: November 23, 2022
• Est. primary completion date: November 23, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Signed and dated informed consent (ICF): a written informed consent must be obtained prior to any study related procedure being performed

• Male and female out-patients aged 18 to 80 years

• GERD diagnosis confirmed through a validated questionnaire (GERDQ score = 8).

• EGD endoscopy performed within 1 year before screening

• Patients in continuous or intermittent treatment with PPI for at least 1 year and continuously for at least 4 weeks prior to study entry

• Patients not fully satisfied with current PPI treatment (1-3 score on 5-points Likert scale)

Exclusion Criteria:

• Dyspeptic patients or patients with overlapping symptoms with GI diseases other than GERD

• Histological evidence of Barrett's oesophagus > 1 cm in EGD endoscopy

• Peptic stricture in EGD endoscopy

• Concurrent findings in the EGD endoscopy that might interfere with the participation to the study (e.g cancer, peptic ulcer) as judged by the investigator

• Known impaired kidney or liver function at screening

• Presence of any relevant severe condition or clinically relevant abnormal parameters that in the opinion of the investigator may interfere with the participation to the study

• Medication use (including H2 antagonists, alginates, baclofen, NSAIDS, prokinetics, antidepressants) that may interfere with GERD symptom assessment within 2 weeks before the start of the study or during the study

• Pregnancy or breast-feeding

• Females of childbearing potential not employing adequate contraceptive methods

• Active malignancy of any type, or history of a malignancy (patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years before study enrolment are also acceptable)

• History of/or current psychiatric illness that would interfere with ability to comply with protocol requirements or give informed consent

• History of alcohol or drug abuse that would interfere with ability to comply with protocol requirements

• Treatment with any investigational drug within the previous 30 days

Related Conditions & MeSH terms

• Esophagitis, Peptic
• Gastro Esophageal Reflux
• Gastroesophageal Reflux

Intervention

Device:
• Hyaluronic acid with chondroitin sulphate and magnesium trisilicate, 1100 mg melt in mouth tablet
1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks
• Placebo 1100 mg, identically-looking melt in mouth tablet
1 tablet q.i.d. (three after meals, one before resting) for 3 consecutive weeks

Locations

Country	Name	City	State
Germany	Klinikum Region Hannover (KRH) Klinikum Siloah	Hannover
Germany	Diakonie Klinikum GmbH - Jung- Stilling Krankenhaus	Siegen	Nordrhein-Westfalen

Sponsors (1)

Lead Sponsor	Collaborator
SOFAR S.p.A.

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall patient satisfaction	The percentage of patients with an improvement of at least 2 points in the patient satisfaction measured with a 1 to 5 Likert scale (1 worst satisfaction, 5 best satisfaction)	From baseline to the end of the respective 3-week treatment period
Secondary	Change of weekly frequency of each symptom using the Gastro Esophageal Reflux Disease Questionnaire (GERDQ) questionnaire	The reduction of weekly frequency score (points) for each symptom (score from 0 to 3, where higher scores mean a worse outcome) assessed by GERDQ questionnaire.; Frequency score (points) for symptom: 0=0 day, 1=1 day, 2=2-3 days, 3=4-7 days; How often did you have a burning feeling behind your breastbone (heartburn)? 0 1 2 3; How often did you have stomach contents (liquid or food) moving upwards to your throat or mouth (regurgitation)? 0 1 2 3; How often did you have a pain in the centre of the upper stomach? 3 2 1 0; How often did you have nausea? 3 2 1 0; How often did you have difficulty getting a good night's sleep because of your heartburn and / or regurgitation? 0 1 2 3; How often did you take additional medication for your heartburn and / or regurgitation, other than what the physician told you to take? (such as Tums, Rolaids, Maalox?) 0 1 2 3	From baseline to the end of the respective 3-week treatment period
Secondary	Change of weekly global score of symptoms using the Gastro Esophageal Reflux Disease Questionnaire (GERDQ) questionnaire	The reduction of global score of GERQ questionnaire (score from 0 to 18, where higher scores mean a worse outcome). Global score is obtained as sum score of the 6 items detailed in Outcome 2.	From baseline to the end of the respective 3-week treatment period
Secondary	Change of the intensity of each symptom using the Reflux Symptom Index (RSI) questionnaire	The reduction of score of each symptom (from 0 to 5, where 0 = No problem and 5 = Severe Problem) assessed by RSI questionnaire; Hoarseness or a problem with voice; Cleaning throat; Excess throat mucus or postnasal drip; Difficulty swallowing food, liquids, or pills; Coughing after eating or after lying down; Breathing difficulties or chocking episodes; Troublesome or annoying cough; Sensations of something sticking or a lump in the throat; Heartburn, chest pain, indigestion or stomach acid coming up	From baseline to the end of the respective 3-week treatment period
Secondary	Change of the global score using the Reflux Symptom Index (RSI) questionnaire	The reduction of global score of RSI questionnaire (from 0 to 45, where higher scores mean a worse outcome). Global score is obtained as sum score of the 9 items detailed in Outcome 4.	From baseline to the end of the respective 3-week treatment period
Secondary	Assessment of palatability	The score of taste through a 4-point qualitative scale (where 1 - taste as bad as possible, and 4 - taste as good as possible)	At the end of 3-week treatment period
Secondary	Evaluation of the intake of rescue medications	The amount of rescue medications taken	From V1 (randomization) to V4 (Day 63 +/- 2 days)